Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Isabel Aldir, Ana Horta & Margarida Serrado. (2014) Single-tablet regimens in HIV: does it really make a difference?. Current Medical Research and Opinion 30:1, pages 89-97.
Read now
Read now
Gabriel Rebick & Sharon L Walmsley. (2012) Issues in resistance, adherence, and comparative efficacy of the single-tablet regimen combination of tenofovir, emtricitabine, and efavirenz in the management of HIV-1 infection. Virus Adaptation and Treatment 4, pages 51-63.
Read now
Read now
Brookie M Best & Miguel Goicoechea. (2008) Efavirenz – Still First-line King?. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 965-972.
Read now
Read now
Articles from other publishers (22)
Umay Balcı, Ülkü Üser, Alper Tahmaz & Figen Sarigul Yildirim. (2023) Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey. Cureus.
Crossref
Crossref
Stefano Agnello, Michael Brand, Mathieu F. Chellat, Silvia Gazzola & Rainer Riedl. (2019) A Structural View on Medicinal Chemistry Strategies against Drug Resistance. Angewandte Chemie International Edition 58:11, pages 3300-3345.
Crossref
Crossref
Stefano Agnello, Michael Brand, Mathieu F. Chellat, Silvia Gazzola & Rainer Riedl. (2019) Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. Angewandte Chemie 131:11, pages 3336-3383.
Crossref
Crossref
Laurent Cotte, Tristan Ferry, Pascal Pugliese, Marc-Antoine Valantin, Clotilde Allavena, André Cabié, Isabelle Poizot-Martin, David Rey, Claudine Duvivier, Antoine Cheret, Pierre Dellamonica, Pierre Pradat & Jean-Jacques Parienti. (2017) Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study. PLOS ONE 12:2, pages e0170661.
Crossref
Crossref
María Inés Figueroa, Omar Sued & Pedro Cahn. (2014) What to do Next? Second-line Antiretroviral Therapy. Current Treatment Options in Infectious Diseases 6:2, pages 159-170.
Crossref
Crossref
Maria Brandmann, Uwe Nehls & Ralf Dringen. (2013) 8-Hydroxy-efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes. Neurochemical Research 38:12, pages 2524-2534.
Crossref
Crossref
G. Pistone, A. Pistone, D. Sorbello, E. Viviano & M.R. Bongiorno. (2013) Cutaneous Adverse Reactions to Highly Antiretroviral Therapy in HIV-Positive Patients. Case Reports in Dermatology 6:2, pages 145-149.
Crossref
Crossref
Hadija H Semvua & Gibson S Kibiki. (2011) AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. BMC Research Notes 4:1.
Crossref
Crossref
Hao Zhu & Yaning Wang. (2011) Evaluation of false positive rate based on exposure–response analyses for two compounds in fixed-dose combination products. Journal of Pharmacokinetics and Pharmacodynamics 38:6, pages 671-696.
Crossref
Crossref
Stefano Alcaro, Claudia Alteri, Anna Artese, Francesca Ceccherini-Silberstein, Giosuè Costa, Francesco Ortuso, Lucia Parrotta, Carlo Federico Perno & Valentina Svicher. (2011) Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase. Drug Resistance Updates 14:3, pages 141-149.
Crossref
Crossref
Jennifer King, Matthew McCall, Anthony Cannella, Michael Anne Markiewicz, Amanda James, Chantelle B Hood & Edward P Acosta. (2011) A Randomized Crossover Study to Determine Relative Bioequivalence of Tenofovir, Emtricitabine, and Efavirenz (Atripla) Fixed-Dose Combination Tablet Compared With a Compounded Oral Liquid Formulation Derived From the Tablet. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:5, pages e131-e132.
Crossref
Crossref
S. Moreno, J. Lopez Aldeguer, J. R. Arribas, P. Domingo, J. A. Iribarren, E. Ribera, A. Rivero & F. Pulido. (2010) The future of antiretroviral therapy: challenges and needs. Journal of Antimicrobial Chemotherapy 65:5, pages 827-835.
Crossref
Crossref
Marie-Pierre de Béthune. (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009). Antiviral Research 85:1, pages 75-90.
Crossref
Crossref
Itziar Oyagüez, Miguel A. Casado, Manuel Cotarelo, Antonio Ramírez-Arellano & Josep Mallolas. (2009) Impacto presupuestario de una combinación a dosis fija de efavirenz-emtricitabina-tenofovir para tratamiento de pacientes infectados por el virus de la inmunodeficiencia humana tipo 1. Farmacia Hospitalaria 33:5, pages 247-256.
Crossref
Crossref
Dirk-Jan Wiegman, Kees Brinkman & Eric JF Franssen. (2009) Interaction of Ginkgo biloba with efavirenz. AIDS 23:9, pages 1184-1185.
Crossref
Crossref
Dirk Jochmans, Johan Vingerhoets, Eric Arnoult, Luc Geeraert & Jérôme Guillemont. 2009. Antiviral Research. Antiviral Research
33
50
.
Itziar Oyagüez, Miguel A. Casado, Manuel Cotarelo, Antonio Ramírez-Arellano & Josep Mallolas. (2009) Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1. Farmacia Hospitalaria (English Edition) 33:5, pages 247-256.
Crossref
Crossref
Vassil St. Georgiev. 2009. National Institute of Allergy and Infectious Diseases, NIH. National Institute of Allergy and Infectious Diseases, NIH
415
514
.
Scott D Cohen, Lakhmir S Chawla & Paul L Kimmel. (2008) Acute kidney injury in patients with human immunodeficiency virus infection. Current Opinion in Critical Care 14:6, pages 647-653.
Crossref
Crossref
Roberto ManfrediLeonardo Calza. (2008) Recent Availability of Two Novel, Fixed Formulations of Antiretroviral Nucleoside Analogues: A 12-Month Prospective, Open-Label Survey of Their Practical Use and Therapeutic Perspectives in Antiretroviral-Naive and -Experienced Patients. AIDS Patient Care and STDs 22:4, pages 279-290.
Crossref
Crossref
Zandrea Ambrose, Sarah Palmer, Valerie F. Boltz, Mary Kearney, Kay Larsen, Patricia Polacino, Leon Flanary, Kelli Oswald, Michael PiatakJr.Jr., Jeremy Smedley, Wei Shao, Norbert Bischofberger, Frank Maldarelli, Jason T. Kimata, John W. Mellors, Shiu-Lok Hu, John M. Coffin, Jeffrey D. Lifson & Vineet N. KewalRamani. (2007) Suppression of Viremia and Evolution of Human Immunodeficiency Virus Type 1 Drug Resistance in a Macaque Model for Antiretroviral Therapy. Journal of Virology 81:22, pages 12145-12155.
Crossref
Crossref
Courtney V Fletcher. (2007) Translating Efficacy into Effectiveness in Antiretroviral Therapy. Drugs 67:14, pages 1969-1979.
Crossref
Crossref